Shore granted US patent for autoinjector trainer design
Published: 17 June 2024
We’re proud to announce that we’ve been granted a US patent for our autoinjector trainer device. This builds on our existing UK patent offering pharmaceutical customers complete flexibility and customisation.
The ground-breaking technology, developed for multiple delivery volumes (1.0 ml,2.25 ml & 5.5 ml), mimics a parent device in feel, form, and function. This enables healthcare professionals (HCPs), caregivers, and patients to learn the handling steps and delivery techniques before using the real device.
It mirrors specific injection speeds, fill volumes, and actuation and delivery force profiles to provide a seamless training experience. Not only is the device easy-to-use but it is reusable as it can be reset between use. It’s one of the most effective demonstration and training tools on the market today.
Nick Foley, Founder and Managing Director of Shore: “Complementing our device development with our offering of training devices ensures that our customers are providing their customers with the skills and confidence they need to administer drugs effectively. The granting of the US patent is a great milestone, and we’re pleased to add this recognition to our portfolio. It’s a testament to our team’s expertise.”
Autoinjectors aren’t the only trainers we provide. Our portfolio includes nasal spray and powder devices, patient-controlled injectors, single-dose injectors and electronic training devices. You can view the portfolio of devices on our LinkedIn product page here.
Or read more about training and demo devices here on our website.
